Capricor Takes Legal Action to Wrest Control of DMD Therapy From Partner
09.05.2026 - 00:11:23 | boerse-global.de
The partnership between Capricor Therapeutics and Nippon Shinyaku has unraveled in spectacular fashion, with the California-based biotech filing a lawsuit in early May to terminate their US distribution agreement for the experimental Duchenne muscular dystrophy (DMD) therapy Deramiocel.
Capricor brought the case before the Superior Court in New Jersey, seeking to reclaim full control over the commercial strategy for its lead asset. The move comes as the company prepares to go it alone, building out its own sales infrastructure ahead of a pivotal FDA decision penciled in for August 2026.
Pricing Dispute Threatens Patient Access
At the heart of the conflict lies a fundamental disagreement over the economics of the original deal. Capricor alleges that Nippon Shinyaku and its subsidiary NS Pharma made a "fundamental calculation error" in the contract's pricing structure, one that would render Deramiocel unaffordable for patients covered by either government programs like Medicare or private insurers.
The complaint warns that the flawed pricing model jeopardizes access for roughly 15,000 DMD patients in the US. Attempts to renegotiate the terms have failed, with NS Pharma refusing to budge, according to court documents.
Should investors sell immediately? Or is it worth buying Capricor Therapeutics?
Beyond the pricing row, Capricor accuses its partner of inadequate preparation for the commercial launch. NS Pharma allegedly halted critical pre-launch testing and failed to provide sufficient financial modeling or transparency around sub-distributors. The company blames a regulatory setback in the summer of 2025 for stalling those preparations.
A Deal Gone Sour
The alliance dates back to 2022, when Nippon Shinyaku paid Capricor $30 million upfront as part of a broader agreement that included potential milestone payments totaling up to $705 million. That arrangement now sits at the center of a legal battle that has sent the stock on a volatile ride.
Nippon Shinyaku has dismissed the allegations as baseless. Capricor, meanwhile, is pressing for an expedited ruling to ensure it can take the reins of the launch without delays that would hurt the DMD community.
Capricor Therapeutics at a turning point? This analysis reveals what investors need to know now.
FDA Timeline Remains Unchanged
The regulatory clock continues to tick regardless of the courtroom drama. The US Food and Drug Administration is reviewing Deramiocel under an accelerated pathway, with data from the HOPE-3 study demonstrating clinical benefits for patients. A final decision is expected in August 2026.
Capricor must resolve the legal uncertainty before that date arrives. The company's upcoming quarterly earnings in May will also be closely watched for clues about its cash position — going solo on commercialization will demand significant capital, and investors will want reassurance that the balance sheet can support the fight on two fronts.
Ad
Capricor Therapeutics Stock: New Analysis - 9 May
Fresh Capricor Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Capricor Aktien ein!
Für. Immer. Kostenlos.
